Evotec expands capacity in Q1

Country

Germany

Evotec SE moved into gene therapy in the 2020 first quarter as part of a strategy to broaden its drug discovery offering to third parties, which include some of the largest pharmaceutical concerns. Explaining the move in a call with analysts on 14 May, Werner Lanthaler, the chief executive, said that companies using its services should have an “unbiased approach” in deciding whether to use small molecules, biologics, or indeed, gene therapy in developing a new medicine.